Financials data is unavailable for this security.
View more
Year on year Genomed SA grew revenues 9.88% from 20.46m to 22.48m while net income improved 174.07% from 337.96k to 926.25k.
Gross margin | 44.00% |
---|---|
Net profit margin | 2.66% |
Operating margin | 4.13% |
Return on assets | 5.77% |
---|---|
Return on equity | 6.56% |
Return on investment | 6.39% |
More ▼
Cash flow in PLNView more
In 2023, Genomed SA increased its cash reserves by 50.81%, or 1.77m. The company earned 1.97m from its operations for a Cash Flow Margin of 8.75%. In addition the company generated 9.53k cash from financing while 203.90k was spent on investing.
Cash flow per share | 0.9039 |
---|---|
Price/Cash flow per share | 30.98 |
Book value per share | 7.02 |
---|---|
Tangible book value per share | 6.95 |
More ▼
Balance sheet in PLNView more
Current ratio | 6.63 |
---|---|
Quick ratio | 4.64 |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼
Growth rates in PLN
Year on year, growth in earnings per share excluding extraordinary items increased 174.07%. Additionally, five year annualized earnings per share growth ranks highest in its industry.
EPS growth(5 years) | -8.94 |
---|---|
EPS (TTM) vs TTM 1 year ago | 113.47 |